Akums Drugs and Pharmaceuticals IPO Subscription Status

Tanushree Jaiswal Tanushree Jaiswal

Last Updated: 2nd August 2024 - 10:32 am

Listen icon

Akums Drugs and Pharmaceuticals IPO Subscription - Day-3 Subscription at 63.44 times

Akums Drugs and Pharmaceuticals IPO closed on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE, NSE. As of 1 Aug 2024, Akums Drugs and Pharmaceuticals IPO received bids for 96,18,57,204 shares much more than the 1,51,62,239 shares offered. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed 63.44 times by the end of day 3.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 3 (1 August 2024 at 6:16 pm): 

Employees (N.A.) QIBs (90.09    X) HNI / NII (42.10X) Retail (20.80X)

Total (63.44X)

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by QIB investors on day 3, followed by High NetWorth Individuals and Non Institutional Investors (NIIs), while retail investors showed less interest on day 3. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market making segment of the IPO. 

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Subscription Status of Akums Drugs and Pharmaceuticals IPO for Days 1, 2, and 3

Date QIB NII Retail Total
Day 1
Jul 30, 2024
0.43 1.97 3.46 1.39
Day 2
Jul 31, 2024
0.96 8.50 9.09 4.46
Day 3
Aug 01, 2024
90.09 42.10 20.80 63.44

On day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. By day 2, the subscription status had risen to 4.46 times and on day 3, it reached 63.44 times.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 3:

Investor Category Subscription (times) Shares Offered Shares Bid For Total Amount (₹ in Crore)
Anchor Investors 1.00 1,22,05,912 1,22,05,912 828.781
QIB Investors 90.09 81,37,276 73,31,17,770 49,778.70
HNIs / NIIs 42.10 40,68,637 17,13,07,510 11,631.78

bNII (bids above ₹10L)

47.43 27,12,425 12,86,49,664 8,735.31

sNII (bids below ₹10L)

31.45 13,56,212 4,26,57,846 2,896.47

Retail Investors

20.80 27,12,424 5,64,23,114 3,831.13
Employees 4.14 2,43,902 10,08,810 68.50
Total 185.82 1,51,62,239 96,18,57,204 65,310.10

Data Source: NSE

For Akums Drugs and Pharmaceuticals IPO Qualified Institutional Buyers (QIBs) showed good interest on day 3 and subscribed 90.09 times. HNIs / NIIs portion subscribed 42.10 times while Retail Investors subscribed 20.80 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 63.44 times on Day 3

Akums Drugs and Pharmaceuticals IPO - Day 2 Subscription at 4.45 Times

Akums Drugs and Pharmaceuticals IPO will close on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE, NSE. By 31 July 2024, Akums Drugs and Pharmaceuticals IPO received bids for 6,74,40,450 shares much more than the 1,51,62,239 shares available. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed by 4.45  times by the end of day 2.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 2 (31st July 2024 at 5:59 pm):

Employees (2.25X) QIBs (0.96X) HNI / NII (8.49X) Retail (9.05X) Total (4.45X)

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by retail investors on day 2, followed by High NetWorth Individuals and Non Institutional Investors (NIIs), at last Qualified Institutional Buyers (QIBs) showed less interest on day 2. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market making segment of the IPO. 

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 2:

Investor Category Subscription (times) Shares Offered Shares Bid For Total Amount (₹ in Crore)
Anchor Investors 1.00 1,22,05,912 1,22,05,912 828.781
QIB Investors 0.96 81,37,276 77,75,702 527.970
HNIs / NIIs 8.49 40,68,637 3,45,58,348 2,346.512
bNII (bids above ₹10L) 8.87 27,12,425 2,40,70,596 1,634.393
sNII (bids below ₹10L) 7.73 13,56,212 1,04,87,752 712.118
Retail Investors 9.05 27,12,424 2,45,58,116 1,667.496
Employees 2.25 2,43,902 5,48,284 37.228
Total 4.45 1,51,62,239 6,74,40,450 4,579.207

Data Source: NSE

On day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. By day 2, the subscription status had risen to 4.45 times. Qualified Institutional Buyers (QIBs) did not show much interest on day 2 and subscribed 0.96 times. HNIs / NIIs portion subscribed 8.49 times while Retail Investors subscribed 9.05 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 4.45 times on Day 2

Akums Drugs and Pharmaceuticals IPO - Day 1 Subscription at 1.39 Times

Akums Drugs and Pharmaceuticals IPO will close on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE and NSE.

On 30 July 2024, Akums Drugs and Pharmaceuticals IPO received bids for 2,11,10,606 shares, much more than the 1,51,62,239 shares available. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed by 1.39 times by the end of Day 1.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 1:

Employees (1.11X) QIBs (0.43X) HNI / NII (1.97X) Retail (3.46X) Total (1.39X)

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by retail investors on Day 1, followed by High Net Worth Individuals and Non-Institutional Investors (NIIs), with Qualified Institutional Buyers (QIBs) showing less interest on Day 1. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market-making segment of the IPO.

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 1:

Investor Category Subscription (times) Shares Offered Shares Bid For Total Amount (₹ in Crore)
Anchor Investors 1 1,22,05,912 1,22,05,912 828.781
QIB Investors 0.43 81,37,276 34,76,242 236.037
HNIs / NIIs 1.97 40,68,637 80,11,388 544.265
bNII (bids above ₹10L) 2.04 27,12,425 55,36,872 375.954
sNII (bids below ₹10L) 1.83 13,56,212 24,74,516 168.020
Retail Investors 3.46 27,12,424 93,75,608 636.604
Employees 1.11 2,43,902 2,69,830 18.321
Total 1.39 1,51,62,239 2,11,10,606 1,433.410

Data Source: NSE

On Day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. Qualified Institutional Buyers (QIBs) did not show much interest on Day 1 and subscribed 0.43 times. HNIs / NIIs portion subscribed 1.97 times while Retail Investors subscribed 3.46 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times.

About Akums Drugs and Pharmaceuticals Ltd

Founded in 2004, Akums Drugs and Pharmaceuticals Limited is a top pharmaceutical contract development and manufacturing organization (CDMO). They offer product development, manufacturing, R&D, regulatory dossier preparation, and testing services, producing and selling branded drugs and APIs.

Akums manufactures various dosage forms, serving 26 of the top 30 Indian pharmaceutical companies in 2023. With 10 manufacturing units and a capacity of 49.21 billion units annually, they plan to add two more units by FY 2025. Their facilities are accredited by EU-GMP, WHO-GMP, and US NSF.

Highlights of Akums Drugs and Pharmaceuticals IPO:

IPO Price Band: ₹646 to ₹679 per share.

Minimum Application Lot Size: 22 shares.

Minimum Investment for Retail Investors: ₹14,938.

Minimum Investment for High Net-worth Investors (HNI): 14 lots (308 shares), ₹209,132.

Registrar: Link Intime India Private Ltd.

Akums Drugs and Pharmaceutical will utilize the net proceeds towards repayment or prepayment of the company's and its subsidiaries’ debts, supporting the company's working capital needs and covering general corporate expenses.

How do you rate this article?
Characters remaining (1500)

FREE Trading & Demat Account
+91
''
By proceeding, you agree to our T&Cs*
Mobile No. belongs to
hero_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Want to Use 5paisa
Trading App?